Navigation Links
Medivation Announces Second Quarter 2010 Financial Results Teleconference and Webcast on August 9, 2010
Date:8/2/2010

SAN FRANCISCO, Aug. 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2010 financial results and provide a general business update on August 9, 2010, at 4:30 p.m. Eastern Time. A press release for the second quarter ended June 30, 2010 will be released after markets close on August 9, 2010.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a clinical development program that includes CONCERT, a Phase 3 trial a
'/>"/>

SOURCE Medivation, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization
2. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
3. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
4. Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
5. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
6. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
7. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
9. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
10. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
11. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... of Kent Hance , the former chancellor of Texas ... retired as chancellor in July 2014, after raising $1.2 billion ... that Kent Hance , the most successful chancellor in ... team not only as an investor, but also as our ...
(Date:9/19/2014)... According to the new ... therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications (Pediatric, ... Global Forecast to 2019" published by MarketsandMarkets, the global ... Million by 2019 from $14,240.0 Million in 2014, ... 2019. Browse 74 market data tables ...
(Date:9/19/2014)... CHICAGO , Sept. 19, 2014  4WEB Medical ... of 3D-printed foot and ankle osteotomy implants on ... and Ankle Society annual meeting in Chicago ... for all of a surgeon,s osteotomy needs with 74 size ... wedge systems had smaller offerings of only 15 to 18 ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Technologies (OTC Bulletin Board: PSTX ), today ... Capital Partners 23rd Annual OC Growth Stock Conference in ... March 13, 2011 at 2PM Pacific (5PM Eastern).  Through ... provides a proven solution for improving patient safety and ...
... 2011 Pioneer Surgical Technology today announces the market launch ... designed to be used in extremity, trauma, and general orthopaedic ... will be showcased during the 2011 American Academy of Orthopaedic ... is a resorbable, collagen-based implant that acts as a ...
Cached Medicine Technology:Patient Safety Technologies, Inc. to Present at the ROTH Capital Partners 23rd Annual OC Growth Stock Conference 2Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities, Trauma, and General Orthopaedics Market with Legato™ Bone Void Filler 2
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- As kids transition from ... of cyberbullies, according to a recent study. ... through 8 found that verbal and physical bullying declines ... bullying intervention and prevention strategies must address all types ... boys and girls, the researchers said. The study was ...
(Date:9/19/2014)... Visiting Nurse Association (VNA) Health Group, ... hospice and palliative care and community-based care, was honored ... yesterday at the New York Stock Exchange. , Founded ... entrepreneur to care for immigrant families suffering from tuberculosis ... to meet the urgent healthcare needs of the communities ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Pregnant women who live ... or low birth weight babies, a new study suggests. ... Canada, and found that expectant mothers who lived in a ... a 20 percent lower risk of very preterm birth (before ... preterm birth (30 to 36 weeks). Babies born to ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Lipitor lawsuits ... caused some patients to develop Type 2 diabetes continue ... underway in U.S. District Court, District of South Carolina, ... issued on September 12, 2014, discovery is underway and ... report noted that Pfizer, Inc., the manufacturer of Lipitor, ...
(Date:9/19/2014)... 2014) - New research published today in the online ... could reach 6,800 in West Africa by the end ... enacted. , Arizona State University and Harvard University ... of rise in cases significantly increased in August in ... quarantine was put in place, indicating that the mass ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Research predicts possible 6,800 new Ebola cases this month 2
... is one of the leading causes of blindness. The cause ... raised pressure within the eye, (the intraocular pressure), that can ... damage results in poor blood supply or weak end eye ... the optic nerve leading to the brain. Fluid enters and ...
... imaging test may identify patients with the gene mutation ... Doppler tissue imaging (DTI) as a more powerful way ... Hypertrophic cardiomyopathy (HCM) causes thickening of the left ventricle ... of sudden cardiac death in the young, affecting one ...
... recent study, the researchers confirmed that people who consume high ... lungs. And for the first time, the research showed that ... decline in lung function over time.// Just like an apple ... may help keep lung disease away, according this new research. ...
... makes detection more easier. A combined scanner detects more ... method. It is notoriously difficult to get an accurate ... is dense and so it's not always possible to ... at the University of Texas now say that combining ...
... to a recent study, a rare genetic condition has uncovered ... unusual childhood genetic disorder marked by bone marrow failure. If ... of a number of cancers, including brain, head and neck, ... and the Children's Hospital, Boston, have been studying a number ...
... Hormone replacement in patch form improves mood and libido ... difficulty reaching orgasm and painful intercourse. They assume it's ... no licensed treatment for these symptoms. ,But a ... California reveals that the patch form of hormone replacement ...
Cached Medicine News:Health News:Vitamin C maintains healthy lungs 2
... Trinity Biotech Captia™ Varicella-Zoster Virus (VZV) IgG ... the detection and quantitative determination of IgG ... serum specimens may be used for the ... and convalescent, may be used to demonstrate ...
Varicella-zoster virus (VZV) IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the detection of IgM antibody to Varicella-zoster virus in human serum as an aid in the diagnosis of primar...
The DSL-05-10-VZM Varicella Zoster IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Varicella Zoster Virus in human serum. This as...
... Mumps IgM Enzyme-Linked Immunosorbent Assay ... qualitative detection of IgM antibody ... for the determination of immunological ... this kit have not been ...
Medicine Products: